Through the accumulation of clinical evidence, SGLT2 inhibitor is currently considered to be a key drug for DM from the perspective of the prevention for future cardiovascular disease (CVD) event [4, 5]. This evidence concerns the gene SLC5A2 and diabetes mellitus.